Revvity (RVTY) is drawing fresh attention after reporting first quarter 2026 results that exceeded analyst expectations on revenue and adjusted EPS, while also lowering full year guidance and moving to divest its China Immunodiagnostics business.

Despite the Q1 beat and corporate moves around guidance, governance and dividends, recent share price performance has been weak, with a 90 day share price return of 14.46% and a 1 year total shareholder return decline of 6.54%, suggesting momentum has been fading even as the underlying story continues to evolve.

If this kind of mixed reaction has you looking beyond a single healthcare stock, it may be a good time to widen your search with 33 healthcare AI stocks

With Revvity stock down over the past year, trading at a discount to both analyst price targets and some intrinsic value estimates, the key question is whether this gap signals an opportunity or whether the current price already reflects its future growth.

Most Popular Narrative: 27.6% Undervalued

Revvity's most followed narrative pegs fair value at $119.56 versus the last close of $86.51, framing a wide gap that rests on a detailed earnings and margin story.

Ongoing shift in product mix toward higher margin, software enabled and consumables driven offerings (e.g., SaaS Signals, reagents, new IDS i20 platform), along with structural cost actions, are expected to materially expand operating and net margins, with 2026 set to start at a higher 28% operating margin baseline.

Want to see what sits behind that margin lift and earnings power story? The narrative leans on measured revenue growth, rising profitability and a reset share count. The exact mix of those assumptions may surprise you.

Result: Fair Value of $119.56 (UNDERVALUED)

However, this depends on China policy and reimbursement trends not putting lasting pressure on diagnostics margins, as well as on academic or government funding pressures not dragging on demand.

Next Steps

With both risks and rewards in the mix, does the current story match your own read of Revvity? Take a closer look at the 3 key rewards and 1 important warning sign

Looking for more investment ideas?

If Revvity has sharpened your focus, do not stop here. The right mix of fresh ideas can help you build a stronger, more resilient portfolio.

• Target future growth potential by scanning for companies analysts flag as mispriced using the 48 high quality undervalued stocks.
• Strengthen your income stream by reviewing stocks that combine higher yields with staying power through the 12 dividend fortresses.
• Reduce portfolio stress by focusing on companies with sturdier finances using the 70 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.